CoChat

Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?

Open access
Lisco, Giuseppe, De Tullio, Anna, Disoteo, Olga, Piazzolla, Giuseppina, Guastamacchia, Edoardo, Sabbà, Carlo, De Geronimo, Vincenzo, Papini, Enrico, Triggiani, Vincenzo · 2023 · Endocrine Connections
Cited by 37

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/ec-23-0257

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 34

  1. Sabouret PBocchino PPAngelini FD’Ascenzo FGalati GFysekidis MFerrari DEFischman DLBhatt DL & Biondi-Zoccai G. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis. Minerva Cardiology and Angiology202371199–207. (https://doi.org/10.23736/S2724-5683.22.05900-2) · DOI · Paper page
  2. Lisco GDe Tullio ADisoteo ODe Geronimo VPiazzolla GDe Pergola GGiagulli VAJirillo EGuastamacchia ESabbà C, Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: a rapid review of randomized controlled trials and meta-analysis. Frontiers in Endocrinology (Lausanne)202213920541. (https://doi.org/10.3389/fendo.2022.920541) · DOI
  3. Liu LChen JWang LChen C & Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Frontiers in Endocrinology (Lausanne)2022131043789. (https://doi.org/10.3389/fendo.2022.1043789) · DOI · Paper page
  4. Bloomgarden Z. Liraglutide and calcitonin. Journal of Diabetes20102223–224. (https://doi.org/10.1111/j.1753-0407.2010.00079.x) · DOI
  5. Rosol TJ. On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice. Toxicologic Pathology201341303–309. (https://doi.org/10.1177/0192623312472402) · DOI · Paper page
  6. Aroda VR & Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes/Metabolism Research and Reviews201127528–542. (https://doi.org/10.1002/dmrr.1202) · DOI · Paper page
  7. Parks M & Rosebraugh C. Weighing risks and benefits of liraglutide – the FDA's review of a new antidiabetic therapy. New England Journal of Medicine2010362774–777. (https://doi.org/10.1056/NEJMp1001578) · DOI · Paper page
  8. Vangoitsenhoven RMathieu C & Van der Schueren B. GLP1 and cancer: friend or foe?Endocrine-Related Cancer201219F77–F88. (https://doi.org/10.1530/ERC-12-0111) · DOI · Paper page
  9. Kannan S & Nasr C. Should we be concerned about thyroid cancer in patients taking glucagon-like peptide 1 receptor agonists?Cleveland Clinic Journal of Medicine201582142–144. (https://doi.org/10.3949/ccjm.81a.13066) · DOI
  10. Hirai KKotani TAratake YOhtaki S & Kuma K. Dipeptidyl peptidase IV (DPP IV/CD26) staining predicts distant metastasis of ‘benign’ thyroid tumor. Pathology International199949264–265. (https://doi.org/10.1046/j.1440-1827.1999.00859.x) · doi:10.1046/j.1440-1827.1999.00859.x
  11. Tanaka TUmeki KYamamoto ISakamoto FNoguchi S & Ohtaki S. CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma. International Journal of Cancer199564326–331. (https://doi.org/10.1002/ijc.2910640508) · DOI
  12. Kholová IRyska ALudvíková MCáp J & Pecen L. Dipeptidyl peptidase IV expression in thyroid cytology: retrospective histologically confirmed study. Cytopathology20031427–31. (https://doi.org/10.1046/j.1365-2303.2003.01138.x) · doi:10.1046/j.1365-2303.2003.01138.x
  13. He LZhang TSun WQin YWang ZDong W & Zhang H. The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway. Medical Oncology20203797. (https://doi.org/10.1007/s12032-020-01419-0) · DOI
  14. Hu XChen SXie CLi ZWu Z & You Z. DPP4 gene silencing inhibits proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells through suppression of the MAPK pathway. Journal of Endocrinological Investigation2021441609–1623. (https://doi.org/10.1007/s40618-020-01455-7) · doi:10.1007/s40618-020-01455-7
  15. Lee JJWang TYLiu CLChien MNChen MJHsu YCLeung CH & Cheng SP. Dipeptidyl peptidase IV as a prognostic marker and therapeutic target in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism20171022930–2940. (https://doi.org/10.1210/jc.2017-00346) · DOI
  16. He QCao HZhao YChen PWang NLi WCui RHou PZhang X & Ji M. Dipeptidyl peptidase-4 stabilizes integrin α4β1 complex to promote thyroid cancer cell metastasis by activating transforming growth factor-beta signaling pathway. Thyroid2022321411–1422. (https://doi.org/10.1089/thy.2022.0317) · DOI
  17. Parola AFDA Advisory Committee Non-clinical Briefing Document. New Drug Application, pp. 22–341. Silver Spring, MD, USA: Food and Drug Administration2009.
  18. Sherman SIKloos RTTuttle RMPontecorvi AVölzke HHarper KVance CAlston JTUsborne ALSloop KW, No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer. Diabetic Medicine201835381–385. (https://doi.org/10.1111/dme.13437) · DOI
  19. Gerstein HCColhoun HMDagenais GRDiaz RLakshmanan MPais PProbstfield JRiesmeyer JSRiddle MCRydén L, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet2019394121–130. (https://doi.org/10.1016/S0140-6736(1931149-3) · DOI
  20. Caparrotta TMTempleton JBClay TAWild SHReynolds RMWebb DJ & Colhoun HM. Glucagon-like peptide 1 receptor agonist (GLP1RA) exposure and outcomes in Type 2 diabetes: a systematic review of population-based observational studies. Diabetes Therapy202112969–989. (https://doi.org/10.1007/s13300-021-01021-1) · DOI
  21. Ahn HSKim HJKim KHLee YSHan SJKim YKo MJ & Brito JP. Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid2016261535–1540. (https://doi.org/10.1089/thy.2016.0075) · DOI · Paper page
  22. Jegerlehner SBulliard JLAujesky DRodondi NGermann SKonzelmann IChiolero A & NICER Working Group. Overdiagnosis and overtreatment of thyroid cancer: a population-based temporal trend study. PLoS One201712e0179387. (https://doi.org/10.1371/journal.pone.0179387) · DOI · Paper page
  23. Dedhia PHSaucke MCLong KLDoherty GM & Pitt SC. Physician perspectives of overdiagnosis and overtreatment of low-risk papillary thyroid cancer in the US. JAMA Network Open20225e228722. (https://doi.org/10.1001/jamanetworkopen.2022.8722) · DOI
  24. Nianogo RA & Arah OA. Forecasting obesity and Type 2 diabetes incidence and burden: the ViLA-obesity simulation model. Frontiers in Public Health202210818816. (https://doi.org/10.3389/fpubh.2022.818816) · DOI
  25. Ma JHuang MWang LYe WTong Y & Wang H. Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies. Medical Science Monitor201521283–291. (https://doi.org/10.12659/MSM.892035) · DOI
  26. Zhang FLi YYu XWang XLin ZSong BTian LFeng CShan Z & Teng W. The relationship and gender disparity between thyroid nodules and metabolic syndrome components based on a recent nationwide cross-sectional study and meta-analysis. Frontiers in Endocrinology (Lausanne)202112736972. (https://doi.org/10.3389/fendo.2021.736972) · DOI
  27. Youssef MRReisner ASCAttia ASHussein MHOmar MLaRussa AGalvani CAAboueisha MAbdelgawad MToraih EA, Obesity and the prevention of thyroid cancer: impact of body mass index and weight change on developing thyroid cancer - Pooled results of 24 million cohorts. Oral Oncology2021112105085. (https://doi.org/10.1016/j.oraloncology.2020.105085) · DOI
  28. O'Neill RJAbd Elwahab SKerin MJ & Lowery AJ. Association of BMI with clinicopathological features of papillary thyroid cancer: a systematic review and meta-analysis. World Journal of Surgery2021452805–2815. (https://doi.org/10.1007/s00268-021-06193-2) · DOI
  29. Cui NSun Q & Chen L. A meta-analysis of the influence of body mass index on the clinicopathologic progression of papillary thyroid carcinoma. Medicine (Baltimore)2021100e26882. (https://doi.org/10.1097/MD.0000000000026882) · DOI
  30. Burrage LCMcLeod DSA & Jordan SJ. Obesity and thyroid cancer risk. Current Opinion in Endocrinology, Diabetes, and Obesity2023. (https://doi.org/10.1097/MED.0000000000000825) · DOI
  31. Li BSun SLi JJYuan JPSun SR & Wu Q. Adipose tissue macrophages: implications for obesity-associated cancer. Military Medical Research2023101. (https://doi.org/10.1186/s40779-022-00437-5) · DOI
  32. Demetriou EFokou MFrangos SPapageorgis PEconomides PA & Economides A. Thyroid nodules and obesity. Life (Basel)2023131292. (https://doi.org/10.3390/life13061292) · DOI
  33. Li LRSong JLLiu HQ & Chen C. Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism. Discover. Oncology20231423. (https://doi.org/10.1007/s12672-022-00599-7) · DOI
  34. Franchini FPalatucci GColao AUngaro PMacchia PE & Nettore IC. Obesity and thyroid cancer risk: an update. International Journal of Environmental Research and Public Health2022191116. (https://doi.org/10.3390/ijerph19031116) · DOI

Cited by

See all 37

Metadata

Authors
Lisco, G., De Tullio, A., Disoteo, O., Piazzolla, G., Guastamacchia, E., Sabbà, C., De Geronimo, V., Papini, E., & Triggiani, V.
Venue
Endocrine Connections
Published
2023-09-01
Volume
12
Issue
11
ISSN
2049-3614 (ISSN-L)
OpenAlex
W4386386705
Cited by
37
References
26
FWCI
6.12
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned? https://app.cochat.ai/papers/10.1530/ec-23-0257
The paper
Lisco, G., De Tullio, A., Disoteo, O., Piazzolla, G., Guastamacchia, E., Sabbà, C., De Geronimo, V., Papini, E., & Triggiani, V. (2023). Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned? Endocrine Connections. https://doi.org/10.1530/ec-23-0257

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.